Financial Performance - In the fiscal year 2024, the company reported total revenue of 346 million yuan, representing a year-on-year growth of 36.48% [2] - The net profit attributable to shareholders was a loss of 63.12 million yuan, an improvement from a loss of 125 million yuan in the same period last year [2] - The net cash flow from operating activities was -121 million yuan, an improvement from -153 million yuan in the previous year [2] - The basic earnings per share were -0.15 yuan, with a weighted average return on equity of -3.09% [2][18] Valuation Metrics - As of April 30, 2024, the company's price-to-book ratio (TTM) was approximately 1.22 times, and the price-to-sales ratio (TTM) was about 6.99 times [2] Revenue Composition - The revenue composition for 2024 included 340.7 million yuan from the sale of medical devices and consumables, with minimal contributions from other services and rental payments [12] Cash Flow Analysis - The net cash flow from financing activities was -33.15 million yuan, a decrease of 9.69 million yuan compared to the previous year [22] - The net cash flow from investment activities was 121 million yuan, compared to -541 million yuan in the previous year [22] Asset and Liability Changes - As of the end of 2024, cash and cash equivalents decreased by 10%, while accounts receivable increased by 58.54% [30] - The company saw a significant increase in contract liabilities by 241.53% and accounts payable by 112.32% [33] Financial Ratios - The current ratio was reported at 11.41, and the quick ratio was 11.11, indicating a strong liquidity position [36]